Pulmonary Fibrosis Clinical Trial Pipeline Analysis: Emerging Antifibrotic Therapies and Novel Treatment Approaches Advancing the Future of Pulmonary Fibrosis Therapeutics | DelveInsight

DelveInsight's "Pulmonary Fibrosis - Pipeline Insight, 2026" report provides comprehensive global coverage of available, marketed, and pipeline therapies for Pulmonary Fibrosis across various stages of clinical development. The report highlights the emerging therapy landscape, key pipeline assets, therapeutic assessment, clinical development activities, collaborations, unmet needs, and market dynamics shaping the future of Pulmonary Fibrosis treatment.

Key Takeaways from the Pulmonary Fibrosis Clinical Trial Landscape Report

• DelveInsight's Pulmonary Fibrosis pipeline report depicts an evolving therapeutic landscape with pipeline therapies spanning Phase III, Phase II/III, Phase II, Phase I/II, Phase I, Preclinical, and Discovery stages.
• Key Pulmonary Fibrosis companies include Bristol-Myers Squibb, PureTech Health, Boehringer Ingelheim, Agomab Therapeutics, Pulmongene Ltd., Sarepta Therapeutics/Arrowhead Pharmaceuticals, Syndax Pharmaceuticals/Incyte Corporation, Avalyn Pharma, and siRNAgen Therapeutics Inc.
• Promising Pulmonary Fibrosis pipeline therapies include BMS-986278, LYT-100, BI 1819479, AGMB-447, ARO-MMP7, Axatilimab, AP01, and SRN-001, representing diverse mechanisms and therapeutic approaches.
• BMS-986278, developed by Bristol-Myers Squibb, is a potential first-in-class oral small-molecule lysophosphatidic acid receptor 1 (LPA1) antagonist currently in Phase III development for Pulmonary Fibrosis.
• LYT-100 (deupirfenidone), developed by PureTech Health, is an oral small molecule in Phase III development, while AP01 from Avalyn Pharma and Axatilimab from Syndax Pharmaceuticals/Incyte Corporation are in Phase II development.

Request a sample and discover the recent advances in Pulmonary Fibrosis treatment drugs:
https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Pulmonary Fibrosis?

Pulmonary fibrosis (PF) is a chronic and progressive lung disease characterized by excessive accumulation of extracellular matrix (ECM) and remodeling of the lung architecture. This results in scarring and thickening of lung tissue, impairing gas exchange and causing a gradual decline in respiratory function. Common symptoms include shortness of breath, chronic cough, and fatigue, while radiographic imaging can reveal characteristic patterns of interstitial fibrosis.

The pathogenesis of Pulmonary Fibrosis involves complex interactions between genetic susceptibility, environmental triggers, and abnormal cellular responses. Dysregulation of normal wound-healing mechanisms can result in persistent inflammation, excessive collagen deposition, and progressive fibrosis. Diagnosis requires integration of clinical symptoms, risk factors, radiological findings, and, where appropriate, histological confirmation.

Current management includes pharmacological and non-pharmacological approaches. Pulmonary rehabilitation, incorporating physical exercise, education, and psychological support, plays an important role in improving physical performance, reducing shortness of breath, and enhancing quality of life. The continuing progression of pulmonary fibrosis and limited treatment options highlight the need for therapies targeting underlying fibrotic pathways.

Emerging Pulmonary Fibrosis Drug Profiles

BMS-986278: Bristol-Myers Squibb
BMS-986278 is a potential first-in-class, oral, small-molecule lysophosphatidic acid receptor 1 (LPA1) antagonist being developed as a novel antifibrotic treatment for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). The therapy is designed to inhibit LPA1-mediated signaling pathways involved in pulmonary fibrosis. BMS-986278 is currently in Phase III clinical development.

The Phase III NCT06025578 study was initiated by Bristol-Myers Squibb in October 2023 to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with progressive pulmonary fibrosis. The trial is active, not recruiting, and is expected to be completed in December 2027, with an estimated enrollment of 1,057 participants.

The therapy has also demonstrated encouraging Phase II results. In the PPF cohort, treatment with 60 mg BMS-986278 led to a 69% relative reduction in the rate of change in ppFVC versus placebo in the while-on-treatment analysis, while a 74% relative reduction was observed in the treatment-policy analysis.

LYT-100 (Deupirfenidone): PureTech Health
LYT-100 (deupirfenidone) is an oral small-molecule therapy being developed by PureTech Health for Pulmonary Fibrosis. The therapy is currently in Phase III clinical development and represents one of the leading late-stage assets in the Pulmonary Fibrosis pipeline.
In February 2026, PureTech Health announced that the US FDA and European Commission granted Orphan Drug Designation to deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF). In December 2025, the company announced successful completion of the End-of-Phase 2 meeting with the US FDA regarding the development of LYT-100 for IPF.

BI 1819479: Boehringer Ingelheim
BI 1819479 is an investigational therapy being developed by Boehringer Ingelheim for Pulmonary Fibrosis. The therapy is currently in Phase II development and represents one of the mid-stage assets in the evolving Pulmonary Fibrosis pipeline.

AP01: Avalyn Pharma
AP01 is an investigational small-molecule therapy administered through oral inhalation and currently in Phase II development for Pulmonary Fibrosis. It represents an inhaled therapeutic approach within the emerging antifibrotic pipeline.

Learn more about the novel and emerging Pulmonary Fibrosis pipeline therapies:
https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Pulmonary Fibrosis Clinical Trial Landscape

• In February 2026, Shanghai Ark Biopharmaceutical Co., Ltd. announced that the US FDA cleared its Investigational New Drug (IND) application for AK3280, a novel antifibrotic therapy for idiopathic pulmonary fibrosis (IPF). The clearance enables the company to initiate a Phase II proof-of-concept clinical trial of AK3280 in the United States.
• In February 2026, PureTech Health plc announced that the US FDA and European Commission granted Orphan Drug Designation to deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF).
• In December 2025, PureTech Health plc announced the successful completion of the End-of-Phase 2 (EOP2) meeting with the US FDA regarding the development of deupirfenidone (LYT-100) for IPF.
• In October 2023, Bristol-Myers Squibb initiated the Phase III NCT06025578 study evaluating BMS-986278 in participants with progressive pulmonary fibrosis. The study is active, not recruiting, and is expected to be completed in December 2027, with an estimated enrollment of 1,057 participants.
• In October 2023, the US FDA granted Breakthrough Therapy Designation to BMS-986278 for the treatment of progressive pulmonary fibrosis (PPF). The therapy had also previously received Fast Track and Orphan Drug Designations for IPF.

Scope of the Pulmonary Fibrosis Pipeline Report

• Coverage: Global
• Therapeutic Assessment by Product Type: Monotherapy, Combination Therapy
• Therapeutic Assessment by Clinical Stages: Discovery, Preclinical, Phase I, Phase I/II, Phase II, Phase II/III, Phase III, Pre-registration
• Therapeutic Assessment by Route of Administration: Inhalation, Inhalation/Intravenous, Injection, Intravenous, Intravenous/Subcutaneous, Intranasal, Oral, Parenteral, Subcutaneous
• Therapeutic Assessment by Molecule Type: Small Molecule, Monoclonal Antibody, Gene Therapy, Cell Therapy, Protein, RNA, Peptide, Recombinant Fusion Protein, and others
• Key Pulmonary Fibrosis Companies: Bristol-Myers Squibb, PureTech Health, Boehringer Ingelheim, Agomab Therapeutics, Pulmongene Ltd., Sarepta Therapeutics/Arrowhead Pharmaceuticals, Syndax Pharmaceuticals/Incyte Corporation, Avalyn Pharma, siRNAgen Therapeutics Inc., and others.
• Key Pulmonary Fibrosis Pipeline Therapies: BMS-986278, LYT-100, BI 1819479, AGMB-447, ARO-MMP7, Axatilimab, AP01, SRN-001, and others.

Dive deep into rich insights for emerging Pulmonary Fibrosis therapies, visit:
https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Pulmonary Fibrosis Pipeline Report Introduction
• Pulmonary Fibrosis Pipeline Report Executive Summary
• Pulmonary Fibrosis: Overview
• Analytical Perspective In-depth Commercial Assessment
• Pulmonary Fibrosis Pipeline Therapeutics
• Pulmonary Fibrosis Pipeline: Late Stage Products (Phase III)
• Pulmonary Fibrosis Pipeline: Mid Stage Products (Phase II)
• Pulmonary Fibrosis Pipeline: Early Stage Products (Phase I/II)
• Pulmonary Fibrosis Pipeline: Early Stage Products (Phase I)
• Pulmonary Fibrosis Pipeline: Preclinical Stage Products
• Pulmonary Fibrosis Pipeline: Discovery Stage Products
• Pulmonary Fibrosis Pipeline Therapeutic Assessment
• Inactive Products in the Pulmonary Fibrosis Pipeline
• Collaborations Assessment - Licensing / Partnering / Funding
• Unmet Needs
• Market Drivers and Barriers
• Future Perspectives and Conclusion
• Analyst Views
• Appendix

For further information on the Pulmonary Fibrosis pipeline therapeutics, reach out:
https://www.delveinsight.com/sample-request/pulmonary-fibrosis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant firm serving as a knowledge partner across the pharmaceutical industry value chain. With proprietary databases and analytical models, DelveInsight provides market and pipeline analysis and API intelligence across therapy areas, helping pharmaceutical and biotechnology companies evaluate products, portfolios, and market opportunities.

This release was published on openPR.